RxDoctor Payments Data

Steven Treon

Boston, MANPI 1821060138

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $359,938 of the $366,328 with a category attached, or 98.3%. 17 manufacturers reported payments, led by GSK at 53.6% of the total.

$366,328in general payments, 2019–2025

Across 109 payments — averaging $3360.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$196K
  • E.r. Squibb & Sons, L.L.C.$33K
  • Beigene Switzerland GmbH$29K
  • Pharmacyclics LLC, An Abbvie Company$25K
  • Beigene USA, Inc.$18K
  • Janssen Global Services, LLC$14K
  • plus $51K from 11 others
$1,211,258in research payments, 2019–2025

Across 49 payments — averaging $24,720 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beigene Switzerland GmbH$774K
  • Beigene, Ltd.$172K
  • GSK$134K
  • Pharmacyclics LLC, An Abbvie Company$113K
  • Beone Medicines Ltd.$9K
  • Beone Medicines USA, Inc.$8K

What the payments were for

  • Consulting fees$359,93898%
  • Speaking & faculty fees$2,0001%
  • Travel & lodging$2,3191%
  • Food & beverage$2,0711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →